Screener
Summit Therapeutics SMMT Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Summit Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026. Open the filing →
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
FAQ
- What is Summit Therapeutics's debt-to-equity?
- Summit Therapeutics (SMMT) reported debt-to-equity of 0× in Q1 2026.
- How has Summit Therapeutics's debt-to-equity changed year-over-year?
- Summit Therapeutics's debt-to-equity increased by 96.3% year-over-year, from 0× to 0×.
- What is the long-term trend for Summit Therapeutics's debt-to-equity?
- Over 5 years (2020 to 2025), Summit Therapeutics's debt-to-equity has grown at a 40.0% compound annual growth rate (CAGR), from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Summit Therapeutics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude